for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Celldex Therapeutics Reports Q4 Loss Per Share $0.03

March 7 (Reuters) - Celldex Therapeutics Inc:

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS

* Q4 LOSS PER SHARE $0.03

* CELLDEX THERAPEUTICS - ANTICIPATE TOPLINE PRIMARY ENDPOINT DATA FROM METRIC STUDY OF GLEMBATUMUMAB VEDOTIN WILL BE AVAILABLE IN Q2 OF 2018

* Q4 REVENUE $3.5 MILLION VERSUS $1.9 MILLION Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up